mouse anti proliferating cell nuclear antigen pcna  (Proteintech)

Journal: Biological Research

Article Title: The polyamine inhibitor SAM486A increases the efficacy of adagrasib in non-small cell lung cancer cells harboring KRAS G12C mutation

doi: 10.1186/s40659-026-00679-w

Figure Lengend Snippet: Effect of SAM486A and adagrasib combination therapy on tumor burden and proliferation in a metastatic NSCLC lung model. 500,000 LL2 cells were inoculated into the tail vein of C57BL/6 mice, and the combination (COMBO) of adagrasib (25 mg/kg/day) and SAM486A (25 mg/kg/day) was administered starting at 21 days post-inoculation for 7 days. A Diagram of the experimental design for the adagrasib (ADA) and SAM486A (SAM) combination study. B Representative lung images from control and treated groups. White arrows indicate visible tumors in each lung. C Effect of the adagrasib + SAM486A combination on the number of lung tumors per mouse in each treatment group ( n = 4 mice per group). Data are shown as mean ± SD. No significant differences between groups were observed. D Tumor diameter distribution represented as violin plots, showing the full distribution of individual tumor measurements for each group. ****: p < 0.0001, determined by one-way ANOVA with Dunnett’s post hoc test, comparing the indicated groups. E Representative immunohistochemistry images showing PCNA levels in control and COMBO-treated (adagrasib + SAM486A) tumors. Dashed boxes indicate regions shown at higher magnification. F Quantification of PCNA immunohistochemistry showing the percentage of PCNA-positive cells and mean nuclear PCNA staining intensity in control and COMBO-treated tumors (a.u. : arbitrary units). Numbers above the bars indicate the corresponding p -values, calculated using an unpaired two-tailed t -test with Welch’s correction

Article Snippet: Slides were incubated with a 1:4,000 dilution of anti-proliferating cell nuclear antigen (PCNA) (CAT# 2586S, Cell Signaling) for 30 minutes.

Techniques: Control, Immunohistochemistry, Staining, Two Tailed Test

Journal: International Journal of Molecular Sciences

Article Title: A Pre-Clinical Study on the Use of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor PEP 2-8 to Mitigate Ischemic Injury in a Rat Marginal Donor Model

doi: 10.3390/ijms26188937

Figure Lengend Snippet: PEP 2-8 effect on cell proliferation and apoptosis in control kidneys (CTRL, n = 15) and PEP 2-8 treated kidneys (PEP 2-8, n = 15). ( A ) Top: Box plots represent tubular proliferation index (TPI). TPI was defined as the ratio between the nuclei expressing PCNA and the total nuclei in each tubule, in ten non-consecutive fields from each immunostained kidney (×40 magnification). Data are expressed as median and 2.5–97.5 percentile. Wilcoxon test was performed to compare data from the two study groups. (* p < 0.05) Bottom: Representative sections of PCNA immunostaining (×40 magnification). ( B ) Top: Apoptosis frequency in the two study groups was assessed by counting a total of 1000 tubular cell nuclei per kidney. Results are presented as the percentage of kidneys with cleaved caspase-3 positive (pink) or negative (white) staining. Data from the two groups were compared using Fisher’s exact test. (**** p < 0.0001) Bottom: Representative sections of cleaved caspase 3 immunostaining (40× magnification).

Article Snippet: Following three washes in 150 mM PBS, antigen retrieval was performed by microwaving the sections in citrate buffer pH 6 and then incubated overnight at 4 °C with monoclonal mouse anti-proliferating cell nuclear antigen (PCNA) antibody (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or N-Tyrosine (N-Tyr) antibody (1:100 Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

Techniques: Control, Expressing, Immunostaining, Staining